BACK TO CONTENTS
FOCUS 40
Unlike data capture in other care settings, MURs carry an automatic consent clause to enable details to be shared with their GP (to improve care), and with clinical commissioning groups and NHS England (for service monitoring and payment purposes). Patients must sign this form before a MUR can be carried out.
An example of the value of such data is NHS England’s Medicines Optimisation Dashboard, launched in June this year, which tracks the level of support pharmacies are providing to patients through services such as MURs and the New Medicines Service (NMS).
A study published in the Pharmaceutical Journal recently showed that pharmacist intervention via the NMS increases adherence in new medications by around 10 percent. Such awareness could prompt new approaches to compliance, with pharmacists playing a more formal role.
The most conservative studies state that 25% of patients with long-term conditions don’t use their medications as directed. In diabetes this can be as high as 78%. Community pharmacies not only offer the opportunity to identify people who are unable to use their treatments correctly, but also to fi nd out why.
New product development can also benefi t, as evidenced by the Salford Lung Study, where GSK partnered with pharmacies in Manchester to conduct the world’s fi rst Phase III ‘pragmatic’ randomised controlled trial in asthma and chronic obstructive pulmonary disease. Chris Stirling, the global head of life sciences at KPMG said
WHAT DATA DO COMMUNITY PHARMACIES HOLD?
Levels of patient understanding of their medicines
Ability of patients to use medication or devices correctly
Adherence data such as dosage frequency and reasons for missing doses
Proportion of patients given a service such as a smoking cessation programme or MUR
“Such cooperation is in line with wider efforts by pharmaceutical companies to work more closely with their local communities. Indeed this type of example is just the beginning. Another way to benefi t from this data would be to use it to monitor patients longitudinally, post approval, providing ‘real world’ information on how patients are responding to medicines over time.”
These initiatives should be a catalyst for further use of community pharmacy data. The patient medication records (PMR) systems that regulate stock and dispensing also record a range of frequency, dosage and usage data. This could be crunched through predictive models, with the fi ndings used to anticipate adverse medication incidents and initiate preventive action to avoid hospitalisation.
HOW CAN IT BE USED?
To provide an evidence base for more intervention to increase adherence
Reduce needless hospital admissions
To calculate the return on investment for commissioners of MURs
To highlight the value of pharmacy as a research centre for many stakeholders
To fi nd out more, please contact:
Prof Hilary Thomas
Chief Medical Adviser, KPMG in the UK
+44 (0)20 7311 4154
hilary.thomas@
kpmg.co.uk
Industry stakeholders frequently bemoan the lack of data from GPs and hospitals. A solution to this dilemma already exists – it is now time to use the rich seams of information lying in community pharmacies to drive improved healthcare practices.
© 2014 KPMG LLP, a UK limited liability partnership, and a member fi rm of the KPMG network of independent member fi rms affi liated with KPMG International Cooperative, a Swiss entity. All rights reserved.
COMMUNITY PHARMACIES
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41